10 results about "Basophils+Mast cells" patented technology

The present invention relates to methods for treating chronic inflammatory conditions using a mast cell stabilizing compound. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents.

The application relates to a compound traditional Chinese medicine composition for treating dermatitis of tumor patients, which is prepared from the following raw materials in parts by weight: 20-40 parts by weight of Huangqi, 5-15 parts by weight of Wumei, 5-15 parts by weight of Baishao, 5-15 parts by weight of Dilong and 10-20 parts by weight of Danshen, and a preparation method thereof is disclosed. The application can obviously improve the clinical dermatitis score related to skin lesions, reduce the spleen coefficient index, and also has the functions of reducing the epidermal thickness and inflammatory infiltration such as mast cells in the dermis, and reducing the inflammatory factor level in the skin lesions, which shows that the application can treat dermatitis of tumor patients.

Compositions and methods for treating diseases and conditions mediated by the high affinity IgE receptor (FcεRI) are provided. Also provided are antisense oligomers for modulating splicing of mRNA encoding a MS4A6A protein, optionally in addition to antisense oligomers for modulating splicing of mRNA encoding the FcεRIβ protein, thereby down-regulating cell-surface expression of FcεRI, and uses of the antisense oligomers for inhibiting mast cell degranulation, cytokine release, migration, and proliferation; for inhibiting anaphylaxis reactions in individuals, for treating allergic conditions in individuals, for reducing the incidence of allergic reactions in individuals, for treating individuals at risk of developing anaphylactic reactions, and for treating mast cell-related diseases in individuals.

Mastocytosis is a rare and heterogeneous disorder marked by the abnormal accumulation of mast cells (MCs) in various tissues. Tyrosine kinase inhibitors have shown limited efficacy, suggesting that additional molecular mechanisms are involved. The inventors showed the unexpected expression of AXL in neoplastic mast cells from patients with various forms of mastocytosis. This is particularly noteworthy as AXL expression had never been investigated in mast cells, whether neoplastic or normal. The study demonstrated the role of AXL, particularly in cooperation with KIT D816V to drive mast cell proliferation and resistance to therapies. In an embodiment, the AXL inhibitor bemcentinib (R428) is used in combination with the TKI midostaurin (PKC 412). The AXL-L197M identified in the ASM patient is pro-proliferative, and induces resistance to death in CD34-derived mast cells and in Ba-f3. Furthermore, the results also suggest that a combination of AXL inhibitors and BCL-2 inhibitors may be appropriate for the treatment of mastocytosis. In conclusion, AXL inhibitors can be thus suitable for the treatment of mastocytosis.

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.

The application discloses an intermediate module molecule for activating chimeric antigen receptor effector cells and application thereof, and belongs to the field of biological medicine. The application focuses on developing an intermediate module molecule capable of regulating the activity of chimeric antigen receptor T cells and capable of regulating the interaction between chimeric antigen receptor T cells and target cells. The module molecule comprises: (a) a targeting polypeptide, which is a tumor target binding polypeptide; (b) an exogenous tag molecule, which is capable of being combined with a chimeric antigen receptor on an effector cell, and (C) a linker connecting the targeting polypeptide and the exogenous tag molecule; and the effector cell is selected from the group consisting of dendritic cells, killer dendritic cells, mast cells, natural killer cells, B lymphocytes, T lymphocytes, macrophages and precursor cells thereof.

Provided are an anti-Siglec-8 antibody or antigen-binding fragment, the use thereof in the preparation of a drug for treating a condition mediated by eosinophils and / or mast cells, and a composition and kit containing the anti-Siglec-8 antibody or antigen-binding fragment.

This invention relates to the field of pharmaceutical technology, disclosing the application of *Melastoma candida* polysaccharide in the preparation of drugs for the prevention or treatment of chronic urticaria. This invention is the first to discover that *Melastoma candida* polysaccharide can regulate immune homeostasis, inhibit inflammatory responses, improve skin lesions, and restore intestinal flora balance through multiple pathways. It also inhibits the overactivation of the NGF / TRPV1 / p38 signaling pathway, reduces neurogenic inflammation and mast cell-mediated responses, thereby alleviating the pathological process of chronic urticaria. This broadens the application scope of *Melastoma candida* polysaccharide and provides a new approach for the treatment of allergic skin-related diseases.

A drug delivery system based on sensitized mast cells, its preparation method, and its application are disclosed, along with a pharmaceutical composition and delivery device involving the sensitized mast cell delivery system. This delivery system utilizes the specific recognition of tumor antigens by sensitized mast cells to target and deliver drugs to tumor cells while protecting them from clearance by the circulating immune system. Upon activation by tumor antigens, sensitized mast cells rapidly degranulate to release the drug, thereby enhancing infection response, exerting an oncolytic effect, lysing tumor cells and releasing antigens, and activating an anti-tumor immune response. This delivery system can serve as a promising platform technology for personalized therapy.

This invention provides a mast cell-targeting magnetoelectric hydrogel acupuncture system for acupoint stimulation, its preparation method, and its application, belonging to the technical field of biomedical materials and acupuncture-assisted treatment devices. The invention first synthesizes Fe₃O₄@BaTiO₃–FcεRIA (FBTFA) nanoparticles to achieve mast cell targeting and synergistic stimulation of cells by "mechanical force-electrical energy" under magnetic field induction. Then, it is compounded with a two-component hydrogel. The hydrogel loaded with FBTFA nanoparticles is then loaded into the groove of a threaded needle. After insertion into the local acupoint, the needle is suspended against the thread, achieving precise delivery and local retention of the hydrogel at the acupuncture site, and continuous release of nanoparticles to target subcutaneous mast cells at the acupoint. This invention generates controllable electro-mechanical stimulation under the action of an external magnetic field, inducing degranulation of rat basophilic leukemia granulocytes (RBL-2H3 cells), and achieving a sustained analgesic effect at the rat acupoint through immune-neuro-endocrine circuit regulation.